Last updated: 15 June 2019 at 2:18am EST

Eddie Gray Net Worth




The estimated Net Worth of Eddie Gray is at least $603 Thousand dollars as of 4 February 2017. Eddie Gray owns over 50,000 units of Dynavax Technologies stock worth over $602,778 and over the last 12 years Eddie sold DVAX stock worth over $0.

Eddie Gray DVAX stock SEC Form 4 insiders trading

Eddie has made over 4 trades of the Dynavax Technologies stock since 2014, according to the Form 4 filled with the SEC. Most recently Eddie exercised 50,000 units of DVAX stock worth $545,500 on 4 February 2017.

The largest trade Eddie's ever made was exercising 50,000 units of Dynavax Technologies stock on 4 February 2017 worth over $545,500. On average, Eddie trades about 4,237 units every 48 days since 2013. As of 4 February 2017 Eddie still owns at least 55,250 units of Dynavax Technologies stock.

You can see the complete history of Eddie Gray stock trades at the bottom of the page.



What's Eddie Gray's mailing address?

Eddie's mailing address filed with the SEC is 2929 SEVENTH STREET, SUITE 100, BERKELEY, CA, 94710.

Insiders trading at Dynavax Technologies

Over the last 21 years, insiders at Dynavax Technologies have traded over $196,839,440 worth of Dynavax Technologies stock and bought 2,463,112 units worth $11,318,051 . The most active insiders traders include Andrew A. F. Hack, Partners L P/Ilbiotechnolog..., and James Edeerfield Capital Lp.... On average, Dynavax Technologies executives and independent directors trade stock every 43 days with the average trade being worth of $1,533,390. The most recent stock trade was executed by Francis Cano on 31 May 2024, trading 3,615 units of DVAX stock currently worth $43,127.



What does Dynavax Technologies do?

dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.



Complete history of Eddie Gray stock trades at Dynavax Technologies

Insider
Trans.
Transaction
Total value
Eddie Gray
CEO and Director
Option $200,000
4 Feb 2017
Eddie Gray
CEO and Director
Buy $42,818
20 May 2016
Eddie Gray
CEO and Director
Buy $42,818
20 May 2016
Eddie Gray
CEO and Director
Buy $37,250
14 Aug 2014


Dynavax Technologies executives and stock owners

Dynavax Technologies executives and other stock owners filed with the SEC include: